Table 2.

Linear regression results for N_Δ4mo and N/L_Δ4mo, which were final predictors for OS, based on the characteristics in Table 1.

Characteristics	NΔ4mo				N/LΔ4mo
	R2	Intercept	β	p	R2	p	Intercept	β	p
Age at RT [y]	−4.2E-3	0.08	−1.0E-3	0.51	−2.0E-3	0.39	0.87	4.3E-3	0.39
Chemotherapy type
(ref: Carboplatin/taxol)	1.9E-3	−0.07	0.15	0.27	−2.8E-3	0.43	1.3	−0.18	0.43
(ref: Cisplatin doublets)	0.01	0.07	−0.28	0.12	1.3E-3	0.28	1.3	−0.49	0.28
(ref: Other)	−5.1E-3	7.0E-3	0.03	0.57	0.01	0.13	1.0	0.64	0.13
Gender (ref: Female)	−4.0E-3	−0.02	0.02	0.49	4.0E-3	0.49	0.99	0.10	0.49
GTV [cm3]	8.8E-4	0.10	−4.1E-4	0.29	−5.7E-3	0.61	1.1	2.7E-4	0.61
Histology
(ref: Adeno ca)	−3.2E-3	0.04	−0.07	0.45	−3.6E-3	0.47	1.2	−0.20	0.47
(ref: SCC)	−3.3E-3	−0.02	0.05	0.46	2.0E-4	0.31	0.89	0.38	0.31
KPS	−5.1E-3	0.20	−2.2E-3	0.57	−4.3E-3	0.51	0.24	0.01	0.51
PMD [Gy]	0.03	−0.39	0.02	0.02	−6.8E-3	0.74	60	0.03	0.74
Prescription dose [Gy]	0.01	1.2	−0.02	0.13	−2.4E-3	0.41	1.1	1.1E-3	0.41
Smoking status
(ref: Current)	4.8E-3	0.11	−0.17	0.20	−3.3E-3	0.45	1.3	−0.2	0.45
(ref: Former)	6.1E-3	−0.05	0.19	0.18	−2.6E-3	0.42	1.1	0.2	0.42
Tumor stage (ref: IIIA)	0.03	−0.44	0.29	0.03	0.05	5.9E-3	−0.45	1.0	0.0059*
Tumor location
(ref: inferior)	0.03	−0.05	0.38	0.03	−1.8E-3	0.38	1.1	0.28	0.38
(ref: left)	4.9E-3	−0.05	0.17	0.20	0.01	0.10	0.92	0.60	0.10
(ref: right)	2.2E-3	0.10	−0.14	0.26	0.01	0.10	1.53	−0.60	0.10
(ref: superior)	0.01	0.18	−0.22	0.13	−4.2E-3	0.50	1.1	0.11	0.50

Note: Significance is denoted by p≤0.0045 given eleven comparisons; R² is the coefficient of determination. Abbreviations as in Table 1;

^*Characteristics with the lowest p-value.